Teyi Pharmaceutical Group (002728) Fair Value & Analysis

Healthcare · CN · Market cap 4.2B CNY

Analysis

Teyi Pharmaceutical Group (002728) currently trades at ¥8.02, while our model-based Fair Value estimate is ¥3.50 — implying the stock looks roughly 56.4% overvalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Teyi Pharmaceutical Group Co.,Ltd engages in the research and development, production, and sale of Chinese patented medicines, pharmaceutical preparations, raw materials, and products in the People's Republic of China. The company's products are used in respiratory system, cardiovascular and cerebrovascular, respiratory, cardiovascular, and digestive systems. The company was formerly known as Guangdong Taicheng Pharmaceutical Co., Ltd. and changed its name to Teyi Pharmaceutical Group Co.,Ltd in November 2016. The company was founded in 2002 and is based in Taishan, the People's Republic of China.

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.